Niva Bupa Health delivered a strong Q3 FY26, marked by accelerated growth in new business and an expanding retail market share. Profitability saw a significant YoY improvement, and the combined ratio strengthened due to better expense management, which offset a slight increase in the loss ratio. Management highlighted positive tailwinds from GST changes, strong traction for its new 'Reassure 3.0' product, and ongoing industry-wide initiatives to manage claims costs through standardization, positioning the company for sustained performance.
vs Q4 FY26
Notable Quotes from the Call
Most Confident Moment
We are very confident that we will meet the regulatory requirement on both 1/N accounting and without 1/N accounting for current financial year.
Least Confident Moment
On future EoM regulations: 'To be honest, nobody has an answer to that. I would be just guessing, even if I told you anything on that.'
| Metric | Value | YoY |
|---|---|---|
| PAT (9M IFRS) | ₹208 Cr | +74.0% YoY |
| Combined Ratio (9M IFRS) | 102.9% | — |
| Retail Loss Ratio (9M IFRS) | 66.9% | — |
| Group Loss Ratio (9M) | 62% | — |
| Solvency Ratio | 2.49 ratio | — |
| AUM | ₹9.0K Cr | — |
Segment Breakdown
Share of 9M Growth
| Metric | Latest | Trend |
|---|---|---|
| Solvency Ratio(x) | 2.49 | |
| AUM(crores) | 9670 | |
| Combined Ratio (IFRS) | 101.4% |
| Category | Target | Priority |
|---|---|---|
| Profitability | Return on Equity (ROE)→High teens | Medium |
| Other | Common Rate Empanelled Hospitals→5,000 | High |
| Other | EOM Compliance→Meet regulatory requirement | High |
| Severity | Risk |
|---|---|
medium | Rising Group Business Loss Ratio The group loss ratio increased to 62% from 57% last year. Management is mitigating this by slowing growth in this segment to 12%. Analyst |
medium | Uncertainty around future regulatory action on EoM/Commissions Management stated they have no visibility on potential future changes to distribution cost regulations, indicating an unquantifiable regulatory risk. Analyst |
low | Accounting noise from IGAAP standards Management acknowledged the volatility in IGAAP reporting due to accounting rules and seasonality, strongly guiding analysts to use IFRS for a true view of performance. Analyst |
Areas of Evasion(1)
Niva Bupa reported strong top-line performance with overall growth of 26% and retail growth of 33% for the first nine months of FY26. The momentum accelerated in Q3 with 31% overall growth and a 46% surge in new business. This performance helped the company increase its retail market share to 10% for the 9-month period, up from 9.6% in H1. Management attributed the Q3 strength partly to positive tailwinds from GST changes, which drove both volume growth (29%) and value growth via a 15% ticket size increase.
On an IFRS basis, Profit After Tax (PAT) for the nine months grew 74% YoY to ₹208 crores. The Q3 PAT stood at ₹77 crores, achieved despite a one-off📎 impact of ₹20 crores from new wage codes. The 9-month combined ratio improved by 50 basis points to 102.9%, driven by a 1.6% reduction in the expense ratio which more than offset a 1.1% increase in the loss ratio due to mix changes. The retail loss ratio remained stable at 66.9%.
The company saw broad-based growth across its distribution channels. The direct digital channel was the standout performer, growing 70% in Q3 and 49% for the nine-month period. The agency channel also demonstrated strong momentum with 43% growth in Q3 and 32% for the nine months. The bancassurance and NBFC channel grew at a more moderate 27.5% in Q3 and 19% YTD. In contrast, the group business (B2B employer-employee) grew at a much slower 12%, a deliberate strategy to focus on profitable segments.
Management highlighted successful efforts to manage acquisition costs. The gross commission ratio fell by 2 percentage points from 23% in H1 to 21% in Q3, largely due to passing on the GST impact to distributors. The company is also an active participant in industry-wide initiatives led by the General Insurance Council. These include expanding the common empanelment of hospitals with standardized rates (targeting 5,000 hospitals in 6-9 months) and implementing standard treatment protocols to reduce unnecessary admissions and control claims costs.
Niva Bupa maintains a strong balance sheet. The solvency ratio stood at a healthy 2.49. The company's Assets Under Management (AUM) reached approximately ₹9,000 crores, generating an annualized investment yield of 7.3% for the nine-month period. Management expressed confidence in its capital position, stating the solvency level is as per their plan and should improve in Q4, which is seasonally strong for IGAAP profits.
The recently launched 'Reassure 3.0' product has become the company's fastest-growing product, favored for its unique features like inflation-proofing and comprehensive OPD coverage. On the customer front, the company reported an improvement in its blended Net Promoter Score (NPS) by 5 points to 58. The cashless NPS remains very strong at 67, and the claim settlement ratio is maintained at a best-in-class level of nearly 95%.